You are herePharma News

Pharma News

GVK BIO Announces Successful Completion of Drug Repurposing Efforts to Identify Novel Indications

(21st October, 2014; Business Wire India); GVK Biosciences (GVK BIO) – Asia’s leading integrated Discovery Research and Development organization today announced the successful completion of in-silico based alternative indications of shelved compounds for Takeda Pharmaceutical Company Limited using GVK BIO’s proprietary Drug Repurposing Platform. Taking the project to the next level, GVK BIO and Takeda have jointly agreed to evaluate the pre-clinical proof-of-concept for certain indications of selected therapeutic compounds to develop novel indications for the previously failed compounds.

Workshop on "critical appraisal of research paper" by the Student chapter of ISPOR @ NIPER, Mohali

(21st October, 2014); The student chapter of ISPOR at NIPER, Mohali conducted a workshop on “Critical Appraisal of Research Papers” as a part of the Third International Conference of Pharmacoeconomics and Outcome Research (held on 17-18 Oct 2014 at New Delhi). Critical appraisal of literature helps in ensuring the trustworthiness, value and relevance of published research to apply into practice.

Import ban in India on cosmetics tested on animals

(17th October, 2014); Health Ministry announced the prohibition of import of cosmetics tested on animals just after few months of banning use of cosmetics tested on animals in country. And with this step India become the first country in south Asia for taking this actions.

B.C. Life Sciences Company Opens Facility in India

(15th October, 2014; Business Wire India); A Richmond-based life sciences company that has made important discoveries in cancer, inflammation and central nervous system disorders has opened a new research facility in India to convert these early discoveries into drugs for global use.

Giant Hope for Type I Diabetic patients - Stem cells are converted to Insulin Secreting beta cells

(15th October, 2014); Harvard researchers announced on last Thursday that they have made a giant leap forward in the quest to find a truly effective treatment for type 1 diabetes, a condition that affects an estimated 3 million Americans at a cost of about $15 billion annually with human embryonic stem cells as a starting point, the scientists are for the first time able to produce, in the kind of massive quantities needed for cell transplantation and pharmaceutical purposes, human insulin-producing beta cells equivalent in most every way to normally functioning beta cells.

New Nano-Cocoons Drug Delivery System against Cancer Cells

Biomedical engineering researchers have developed a drug delivery system consisting of nanoscale “cocoons” made of DNA that target cancer cells and trick the cells into absorbing the cocoon before unleashing anticancer drugs. The work was done by researchers at North Carolina State University and the University of North Carolina at Chapel Hill.

Cipla Medpro announces collaboration with world ’s largest generic company - Teva Pharma

(9th October, 2014); Medpro Pharmaceutica (Pty) Ltd - a subsidiary company of Cipla Medpro, the third largest pharmaceutical company in South Africa , yesterday announced that it has entered into a collaboration with Teva Pharmaceuticals (Pty) Ltd, an affiliate of Teva Pharmaceutical Industries Ltd (Teva) - the largest generic pharmaceutical manufacturer in the world with a presence in about 60 countries and approximately 45,000 dedicated employees worldwide. The collaboration is restricted to the territory of South Africa.

Government imposing ban on use of plastic containers in liquid oral preparations

(7th October, 2014); Now in the near future, you may not see liquid orals in plastic containers because central government prohibits use of Polyethylene Terephthalate or Plastic containers for primary packaging of drug formulations in certain cases.

Galderma Initiates U.S. Study of Novel Muscle Relaxant for Aesthetic Dermatology and Cosmetic Surgery

(6th October, 2014; Business Wire India); Galderma, a global healthcare company focused on dermatology, today announced that it has initiated a Phase II clinical trial of a novel muscle relaxant in the United States. The study is investigating the safety and efficacy of Galderma’s internally developed liquid formulation of botulinum toxin in the setting of aesthetic dermatology and cosmetic surgery and will add to the existing Galderma neurotoxin franchise.

Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC

(6th October, 2014); Novartis announced today that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab), in Phase I/II trials of patients with non-small cell lung cancer (NSCLC).